Checks heart rhythm continuously or intermittently during treatment
Part of Genetic & congenital, Heart & circulation clinical trials.
This study compares two ways of monitoring your heart rhythm while you start certain cancer treatments. It may help doctors detect heart rhythm changes earlier and decide which monitoring approach is better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are starting standard treatment: arsenic trioxide for acute promyelocytic leukemia, or capecitabine/ribociclib for a solid tumor
- You are at least 18 years old
- You do not have an allergy to adhesive patches (the sensors stick to your skin)
- You can understand the study and agree to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a wearable heart monitor can help detect heart problems early in people receiving cancer treatment. It may help doctors manage heart health during therapy.
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
This study uses a small device placed under the skin to monitor your heart rhythm while you take a BTK inhibitor for blood cancer. It aims to detect any irregular heartbeats early, so you and your doctor can take action quickly.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This study looks at whether starting certain blood cancer treatments (BTK inhibitors or others like venetoclax) affects heart rhythm. It focuses on people with specific blood cancers who are starting a new treatment, to check for new or worsening atrial fibrillation.
This study helps doctors predict which cancer patients are at higher risk of heart problems from their cancer treatments. By tracking your heart health before, during, and after treatment, researchers can develop better ways to protect your heart.
Hear when a new Long QT Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.